Anti-CD33 CAR-NK92 cells- PersonGen Biomedicine

Drug Profile

Anti-CD33 CAR-NK92 cells- PersonGen Biomedicine

Alternative Names: Anti-CD33 CAR-NK cells; Anti-CD33 CAR-NK92 cells; Anti-CD33 chimeric antigen receptor natural killer cell therapy - PersonGen Biomedicine; Anti-CD33 chimeric antigen receptor natural killer cells - PersonGen Biomedicine; Anti-CD33 chimeric antigen receptor natural killer92 cells - PersonGen Biomedicine; CAR-NK Cell immunotherapy - PersonGen Biomedicine

Latest Information Update: 07 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PersonGen Biomedicine
  • Class CAR-NK cell therapies; Cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action CD33 antigen inhibitors; Gene transference; Natural killer cell receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia

Most Recent Events

  • 01 Oct 2016 Phase-I/II clinical trials in Acute myeloid leukaemia (In adolescents, In adults, In children, In the elderly, Second-line therapy or greater) in China (Parenteral) (NCT02944162)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top